nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—EGFR—dilated cardiomyopathy	0.554	1	CbGaD
Vandetanib—Bosutinib—SIK1—dilated cardiomyopathy	0.00379	0.382	CrCbGaD
Vandetanib—VEGFA—Enalapril—Lisinopril—dilated cardiomyopathy	0.00322	1	CbGdCrCtD
Vandetanib—Anuria—Lisinopril—dilated cardiomyopathy	0.00276	0.0265	CcSEcCtD
Vandetanib—STK35—cardiac ventricle—dilated cardiomyopathy	0.00264	0.0255	CbGeAlD
Vandetanib—Pyelonephritis—Lisinopril—dilated cardiomyopathy	0.00254	0.0244	CcSEcCtD
Vandetanib—STK35—myocardium—dilated cardiomyopathy	0.00248	0.024	CbGeAlD
Vandetanib—VEGFA—cardiac ventricle—dilated cardiomyopathy	0.00243	0.0235	CbGeAlD
Vandetanib—RIPK2—myocardium—dilated cardiomyopathy	0.00229	0.0221	CbGeAlD
Vandetanib—VEGFA—myocardium—dilated cardiomyopathy	0.00228	0.0221	CbGeAlD
Vandetanib—Dysaesthesia—Lisinopril—dilated cardiomyopathy	0.00223	0.0214	CcSEcCtD
Vandetanib—MKNK1—cardiac ventricle—dilated cardiomyopathy	0.00219	0.0211	CbGeAlD
Vandetanib—AXL—cardiac ventricle—dilated cardiomyopathy	0.00215	0.0208	CbGeAlD
Vandetanib—SLK—cardiac ventricle—dilated cardiomyopathy	0.00207	0.02	CbGeAlD
Vandetanib—MKNK1—myocardium—dilated cardiomyopathy	0.00206	0.0199	CbGeAlD
Vandetanib—AXL—myocardium—dilated cardiomyopathy	0.00202	0.0196	CbGeAlD
Vandetanib—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00202	0.0194	CcSEcCtD
Vandetanib—FYN—cardiac ventricle—dilated cardiomyopathy	0.00201	0.0195	CbGeAlD
Vandetanib—Cerebral ischaemia—Lisinopril—dilated cardiomyopathy	0.00199	0.0192	CcSEcCtD
Vandetanib—Bosutinib—RPS6KB1—dilated cardiomyopathy	0.00199	0.201	CrCbGaD
Vandetanib—TEK—cardiac ventricle—dilated cardiomyopathy	0.00197	0.019	CbGeAlD
Vandetanib—SLK—myocardium—dilated cardiomyopathy	0.00195	0.0188	CbGeAlD
Vandetanib—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00191	0.0183	CcSEcCtD
Vandetanib—FYN—myocardium—dilated cardiomyopathy	0.00189	0.0183	CbGeAlD
Vandetanib—TEK—myocardium—dilated cardiomyopathy	0.00185	0.0179	CbGeAlD
Vandetanib—YES1—cardiac ventricle—dilated cardiomyopathy	0.00182	0.0176	CbGeAlD
Vandetanib—FLT3—heart—dilated cardiomyopathy	0.00177	0.0171	CbGeAlD
Vandetanib—Lethargy—Spironolactone—dilated cardiomyopathy	0.00175	0.0168	CcSEcCtD
Vandetanib—STK35—heart—dilated cardiomyopathy	0.00173	0.0168	CbGeAlD
Vandetanib—YES1—myocardium—dilated cardiomyopathy	0.00171	0.0165	CbGeAlD
Vandetanib—ABL2—heart—dilated cardiomyopathy	0.00169	0.0163	CbGeAlD
Vandetanib—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00168	0.0161	CcSEcCtD
Vandetanib—EGFR—heart—dilated cardiomyopathy	0.00165	0.0159	CbGeAlD
Vandetanib—KDR—cardiac ventricle—dilated cardiomyopathy	0.00161	0.0156	CbGeAlD
Vandetanib—FLT4—heart—dilated cardiomyopathy	0.00161	0.0155	CbGeAlD
Vandetanib—RIPK2—heart—dilated cardiomyopathy	0.0016	0.0154	CbGeAlD
Vandetanib—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.0016	0.0154	CcSEcCtD
Vandetanib—Afatinib—EGFR—dilated cardiomyopathy	0.0016	0.161	CrCbGaD
Vandetanib—VEGFA—heart—dilated cardiomyopathy	0.00159	0.0154	CbGeAlD
Vandetanib—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00157	0.0151	CcSEcCtD
Vandetanib—IRAK4—heart—dilated cardiomyopathy	0.00156	0.0151	CbGeAlD
Vandetanib—ERBB3—heart—dilated cardiomyopathy	0.00153	0.0148	CbGeAlD
Vandetanib—Gastritis—Spironolactone—dilated cardiomyopathy	0.00152	0.0146	CcSEcCtD
Vandetanib—KDR—myocardium—dilated cardiomyopathy	0.00151	0.0146	CbGeAlD
Vandetanib—MAP2K5—myocardium—dilated cardiomyopathy	0.00151	0.0146	CbGeAlD
Vandetanib—STK35—cardiac atrium—dilated cardiomyopathy	0.00148	0.0143	CbGeAlD
Vandetanib—MKNK1—heart—dilated cardiomyopathy	0.00144	0.0139	CbGeAlD
Vandetanib—FGR—heart—dilated cardiomyopathy	0.00142	0.0137	CbGeAlD
Vandetanib—RET—heart—dilated cardiomyopathy	0.00142	0.0137	CbGeAlD
Vandetanib—LCK—heart—dilated cardiomyopathy	0.00142	0.0137	CbGeAlD
Vandetanib—AXL—heart—dilated cardiomyopathy	0.00141	0.0137	CbGeAlD
Vandetanib—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.0014	0.0135	CcSEcCtD
Vandetanib—PDGFRB—cardiac ventricle—dilated cardiomyopathy	0.00139	0.0135	CbGeAlD
Vandetanib—FMO3—heart—dilated cardiomyopathy	0.00137	0.0132	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—dilated cardiomyopathy	0.00137	0.0132	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—dilated cardiomyopathy	0.00136	0.0132	CbGeAlD
Vandetanib—SLK—heart—dilated cardiomyopathy	0.00136	0.0131	CbGeAlD
Vandetanib—Laryngitis—Lisinopril—dilated cardiomyopathy	0.00134	0.0128	CcSEcCtD
Vandetanib—FYN—heart—dilated cardiomyopathy	0.00132	0.0128	CbGeAlD
Vandetanib—PDGFRB—myocardium—dilated cardiomyopathy	0.00131	0.0127	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00131	0.0126	CcSEcCtD
Vandetanib—Haemoptysis—Lisinopril—dilated cardiomyopathy	0.0013	0.0125	CcSEcCtD
Vandetanib—Renal failure—Spironolactone—dilated cardiomyopathy	0.0013	0.0125	CcSEcCtD
Vandetanib—TEK—heart—dilated cardiomyopathy	0.00129	0.0125	CbGeAlD
Vandetanib—MAP4K5—heart—dilated cardiomyopathy	0.00129	0.0125	CbGeAlD
Vandetanib—ABL1—cardiac ventricle—dilated cardiomyopathy	0.00124	0.012	CbGeAlD
Vandetanib—EPHB6—heart—dilated cardiomyopathy	0.00124	0.0119	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—dilated cardiomyopathy	0.00123	0.0119	CbGeAlD
Vandetanib—AXL—cardiac atrium—dilated cardiomyopathy	0.00121	0.0117	CbGeAlD
Vandetanib—YES1—heart—dilated cardiomyopathy	0.00119	0.0115	CbGeAlD
Vandetanib—STK10—heart—dilated cardiomyopathy	0.00118	0.0114	CbGeAlD
Vandetanib—ABL1—myocardium—dilated cardiomyopathy	0.00117	0.0113	CbGeAlD
Vandetanib—SLK—cardiac atrium—dilated cardiomyopathy	0.00116	0.0112	CbGeAlD
Vandetanib—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00116	0.0112	CcSEcCtD
Vandetanib—Bladder pain—Furosemide—dilated cardiomyopathy	0.00116	0.0112	CcSEcCtD
Vandetanib—SRC—heart—dilated cardiomyopathy	0.00115	0.0111	CbGeAlD
Vandetanib—FYN—cardiac atrium—dilated cardiomyopathy	0.00113	0.0109	CbGeAlD
Vandetanib—Erlotinib—EGFR—dilated cardiomyopathy	0.00113	0.114	CrCbGaD
Vandetanib—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00112	0.0108	CcSEcCtD
Vandetanib—TEK—cardiac atrium—dilated cardiomyopathy	0.00111	0.0107	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—dilated cardiomyopathy	0.00111	0.0107	CbGeAlD
Vandetanib—Proteinuria—Lisinopril—dilated cardiomyopathy	0.0011	0.0105	CcSEcCtD
Vandetanib—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00108	0.0104	CcSEcCtD
Vandetanib—EPHB6—cardiac atrium—dilated cardiomyopathy	0.00106	0.0102	CbGeAlD
Vandetanib—MAP2K5—heart—dilated cardiomyopathy	0.00106	0.0102	CbGeAlD
Vandetanib—KDR—heart—dilated cardiomyopathy	0.00106	0.0102	CbGeAlD
Vandetanib—Alopecia—Spironolactone—dilated cardiomyopathy	0.00105	0.0101	CcSEcCtD
Vandetanib—YES1—cardiac atrium—dilated cardiomyopathy	0.00102	0.00987	CbGeAlD
Vandetanib—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00101	0.00973	CcSEcCtD
Vandetanib—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000992	0.00953	CcSEcCtD
Vandetanib—SRC—cardiac atrium—dilated cardiomyopathy	0.000982	0.00949	CbGeAlD
Vandetanib—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.000976	0.00937	CcSEcCtD
Vandetanib—Lethargy—Furosemide—dilated cardiomyopathy	0.000951	0.00914	CcSEcCtD
Vandetanib—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.000941	0.00905	CcSEcCtD
Vandetanib—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000936	0.00899	CcSEcCtD
Vandetanib—Cystitis—Lisinopril—dilated cardiomyopathy	0.000931	0.00894	CcSEcCtD
Vandetanib—PDGFRB—heart—dilated cardiomyopathy	0.000914	0.00884	CbGeAlD
Vandetanib—KDR—cardiac atrium—dilated cardiomyopathy	0.000903	0.00873	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—dilated cardiomyopathy	0.000903	0.00873	CbGeAlD
Vandetanib—ABCC1—myocardium—dilated cardiomyopathy	0.000889	0.0086	CbGeAlD
Vandetanib—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.000874	0.00839	CcSEcCtD
Vandetanib—Bladder pain—Lisinopril—dilated cardiomyopathy	0.000871	0.00837	CcSEcCtD
Vandetanib—Dehydration—Furosemide—dilated cardiomyopathy	0.000867	0.00833	CcSEcCtD
Vandetanib—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000849	0.00815	CcSEcCtD
Vandetanib—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000825	0.00792	CcSEcCtD
Vandetanib—ABL1—heart—dilated cardiomyopathy	0.000815	0.00788	CbGeAlD
Vandetanib—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00079	0.00759	CcSEcCtD
Vandetanib—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000789	0.00758	CcSEcCtD
Vandetanib—PDGFRB—cardiac atrium—dilated cardiomyopathy	0.000782	0.00756	CbGeAlD
Vandetanib—ALB—heart—dilated cardiomyopathy	0.000752	0.00727	CbGeAlD
Vandetanib—Pollakiuria—Furosemide—dilated cardiomyopathy	0.000744	0.00715	CcSEcCtD
Vandetanib—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000738	0.00709	CcSEcCtD
Vandetanib—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000736	0.00707	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000727	0.00699	CcSEcCtD
Vandetanib—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000727	0.00698	CcSEcCtD
Vandetanib—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.000717	0.00689	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.000712	0.00684	CcSEcCtD
Vandetanib—Gefitinib—EGFR—dilated cardiomyopathy	0.000707	0.0713	CrCbGaD
Vandetanib—Renal failure—Furosemide—dilated cardiomyopathy	0.000706	0.00679	CcSEcCtD
Vandetanib—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000702	0.00675	CcSEcCtD
Vandetanib—ABL1—cardiac atrium—dilated cardiomyopathy	0.000697	0.00674	CbGeAlD
Vandetanib—Bosutinib—EGFR—dilated cardiomyopathy	0.000696	0.0702	CrCbGaD
Vandetanib—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00068	0.00653	CcSEcCtD
Vandetanib—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000666	0.0064	CcSEcCtD
Vandetanib—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000665	0.00639	CcSEcCtD
Vandetanib—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000655	0.0063	CcSEcCtD
Vandetanib—Dehydration—Lisinopril—dilated cardiomyopathy	0.000651	0.00625	CcSEcCtD
Vandetanib—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000637	0.00612	CcSEcCtD
Vandetanib—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000632	0.00608	CcSEcCtD
Vandetanib—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000626	0.00601	CcSEcCtD
Vandetanib—Visual impairment—Furosemide—dilated cardiomyopathy	0.000622	0.00597	CcSEcCtD
Vandetanib—ABCC1—heart—dilated cardiomyopathy	0.000621	0.006	CbGeAlD
Vandetanib—Gastritis—Lisinopril—dilated cardiomyopathy	0.000619	0.00595	CcSEcCtD
Vandetanib—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00061	0.00586	CcSEcCtD
Vandetanib—Influenza—Lisinopril—dilated cardiomyopathy	0.000605	0.00581	CcSEcCtD
Vandetanib—Eye disorder—Furosemide—dilated cardiomyopathy	0.000603	0.00579	CcSEcCtD
Vandetanib—Pruritus—Spironolactone—dilated cardiomyopathy	0.000596	0.00573	CcSEcCtD
Vandetanib—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.000595	0.00571	CcSEcCtD
Vandetanib—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000593	0.0057	CcSEcCtD
Vandetanib—Angiopathy—Furosemide—dilated cardiomyopathy	0.000585	0.00562	CcSEcCtD
Vandetanib—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000582	0.00559	CcSEcCtD
Vandetanib—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000576	0.00554	CcSEcCtD
Vandetanib—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000576	0.00554	CcSEcCtD
Vandetanib—Dysuria—Lisinopril—dilated cardiomyopathy	0.000565	0.00543	CcSEcCtD
Vandetanib—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000565	0.00543	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.000562	0.0054	CcSEcCtD
Vandetanib—Malnutrition—Furosemide—dilated cardiomyopathy	0.000562	0.0054	CcSEcCtD
Vandetanib—Dizziness—Spironolactone—dilated cardiomyopathy	0.000557	0.00535	CcSEcCtD
Vandetanib—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000552	0.0053	CcSEcCtD
Vandetanib—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00055	0.00528	CcSEcCtD
Vandetanib—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000547	0.00526	CcSEcCtD
Vandetanib—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000545	0.00524	CcSEcCtD
Vandetanib—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000542	0.00521	CcSEcCtD
Vandetanib—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00054	0.00519	CcSEcCtD
Vandetanib—Depression—Lisinopril—dilated cardiomyopathy	0.000538	0.00517	CcSEcCtD
Vandetanib—Vomiting—Spironolactone—dilated cardiomyopathy	0.000536	0.00515	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000534	0.00514	CcSEcCtD
Vandetanib—Rash—Spironolactone—dilated cardiomyopathy	0.000531	0.0051	CcSEcCtD
Vandetanib—ABCC1—cardiac atrium—dilated cardiomyopathy	0.000531	0.00513	CbGeAlD
Vandetanib—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000531	0.0051	CcSEcCtD
Vandetanib—Renal failure—Lisinopril—dilated cardiomyopathy	0.00053	0.00509	CcSEcCtD
Vandetanib—Vision blurred—Furosemide—dilated cardiomyopathy	0.000529	0.00508	CcSEcCtD
Vandetanib—Headache—Spironolactone—dilated cardiomyopathy	0.000528	0.00507	CcSEcCtD
Vandetanib—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000524	0.00504	CcSEcCtD
Vandetanib—Haematuria—Lisinopril—dilated cardiomyopathy	0.000514	0.00494	CcSEcCtD
Vandetanib—ABCG2—heart—dilated cardiomyopathy	0.000514	0.00497	CbGeAlD
Vandetanib—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00051	0.0049	CcSEcCtD
Vandetanib—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000509	0.00489	CcSEcCtD
Vandetanib—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000506	0.00486	CcSEcCtD
Vandetanib—Nausea—Spironolactone—dilated cardiomyopathy	0.0005	0.00481	CcSEcCtD
Vandetanib—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000493	0.00473	CcSEcCtD
Vandetanib—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000478	0.00459	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000475	0.00456	CcSEcCtD
Vandetanib—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000474	0.00456	CcSEcCtD
Vandetanib—Dry mouth—Furosemide—dilated cardiomyopathy	0.000468	0.00449	CcSEcCtD
Vandetanib—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000458	0.0044	CcSEcCtD
Vandetanib—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000449	0.00432	CcSEcCtD
Vandetanib—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000449	0.00431	CcSEcCtD
Vandetanib—Skin disorder—Furosemide—dilated cardiomyopathy	0.000445	0.00428	CcSEcCtD
Vandetanib—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000439	0.00422	CcSEcCtD
Vandetanib—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000436	0.00419	CcSEcCtD
Vandetanib—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000432	0.00415	CcSEcCtD
Vandetanib—Alopecia—Lisinopril—dilated cardiomyopathy	0.000428	0.00411	CcSEcCtD
Vandetanib—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000424	0.00407	CcSEcCtD
Vandetanib—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000421	0.00405	CcSEcCtD
Vandetanib—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000413	0.00396	CcSEcCtD
Vandetanib—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000412	0.00395	CcSEcCtD
Vandetanib—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000405	0.00389	CcSEcCtD
Vandetanib—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000398	0.00383	CcSEcCtD
Vandetanib—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000397	0.00382	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000396	0.0038	CcSEcCtD
Vandetanib—Fatigue—Furosemide—dilated cardiomyopathy	0.000395	0.0038	CcSEcCtD
Vandetanib—Tremor—Lisinopril—dilated cardiomyopathy	0.000395	0.00379	CcSEcCtD
Vandetanib—Pain—Furosemide—dilated cardiomyopathy	0.000392	0.00377	CcSEcCtD
Vandetanib—Constipation—Furosemide—dilated cardiomyopathy	0.000392	0.00377	CcSEcCtD
Vandetanib—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000375	0.0036	CcSEcCtD
Vandetanib—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00037	0.00356	CcSEcCtD
Vandetanib—Cough—Lisinopril—dilated cardiomyopathy	0.000368	0.00353	CcSEcCtD
Vandetanib—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000362	0.00348	CcSEcCtD
Vandetanib—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000362	0.00348	CcSEcCtD
Vandetanib—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000359	0.00345	CcSEcCtD
Vandetanib—Chest pain—Lisinopril—dilated cardiomyopathy	0.000359	0.00345	CcSEcCtD
Vandetanib—Anxiety—Lisinopril—dilated cardiomyopathy	0.000357	0.00343	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000356	0.00342	CcSEcCtD
Vandetanib—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000351	0.00337	CcSEcCtD
Vandetanib—Oedema—Lisinopril—dilated cardiomyopathy	0.000344	0.0033	CcSEcCtD
Vandetanib—Infection—Lisinopril—dilated cardiomyopathy	0.000342	0.00328	CcSEcCtD
Vandetanib—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000337	0.00323	CcSEcCtD
Vandetanib—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000334	0.00321	CcSEcCtD
Vandetanib—Asthenia—Furosemide—dilated cardiomyopathy	0.000329	0.00316	CcSEcCtD
Vandetanib—Pruritus—Furosemide—dilated cardiomyopathy	0.000324	0.00312	CcSEcCtD
Vandetanib—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000314	0.00301	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000313	0.00301	CcSEcCtD
Vandetanib—Insomnia—Lisinopril—dilated cardiomyopathy	0.000311	0.00299	CcSEcCtD
Vandetanib—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000309	0.00297	CcSEcCtD
Vandetanib—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000307	0.00295	CcSEcCtD
Vandetanib—Dizziness—Furosemide—dilated cardiomyopathy	0.000303	0.00291	CcSEcCtD
Vandetanib—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000303	0.00291	CcSEcCtD
Vandetanib—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000299	0.00287	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000297	0.00285	CcSEcCtD
Vandetanib—Fatigue—Lisinopril—dilated cardiomyopathy	0.000296	0.00285	CcSEcCtD
Vandetanib—Constipation—Lisinopril—dilated cardiomyopathy	0.000294	0.00283	CcSEcCtD
Vandetanib—Pain—Lisinopril—dilated cardiomyopathy	0.000294	0.00283	CcSEcCtD
Vandetanib—Vomiting—Furosemide—dilated cardiomyopathy	0.000291	0.0028	CcSEcCtD
Vandetanib—Rash—Furosemide—dilated cardiomyopathy	0.000289	0.00278	CcSEcCtD
Vandetanib—Dermatitis—Furosemide—dilated cardiomyopathy	0.000289	0.00277	CcSEcCtD
Vandetanib—Headache—Furosemide—dilated cardiomyopathy	0.000287	0.00276	CcSEcCtD
Vandetanib—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000281	0.0027	CcSEcCtD
Vandetanib—Nausea—Furosemide—dilated cardiomyopathy	0.000272	0.00262	CcSEcCtD
Vandetanib—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000272	0.00261	CcSEcCtD
Vandetanib—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000272	0.00261	CcSEcCtD
Vandetanib—Asthenia—Lisinopril—dilated cardiomyopathy	0.000247	0.00237	CcSEcCtD
Vandetanib—Pruritus—Lisinopril—dilated cardiomyopathy	0.000243	0.00234	CcSEcCtD
Vandetanib—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000235	0.00226	CcSEcCtD
Vandetanib—Dizziness—Lisinopril—dilated cardiomyopathy	0.000227	0.00218	CcSEcCtD
Vandetanib—Vomiting—Lisinopril—dilated cardiomyopathy	0.000219	0.0021	CcSEcCtD
Vandetanib—Rash—Lisinopril—dilated cardiomyopathy	0.000217	0.00208	CcSEcCtD
Vandetanib—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000217	0.00208	CcSEcCtD
Vandetanib—Headache—Lisinopril—dilated cardiomyopathy	0.000215	0.00207	CcSEcCtD
Vandetanib—Nausea—Lisinopril—dilated cardiomyopathy	0.000204	0.00196	CcSEcCtD
Vandetanib—ABL1—Immune System—ITGB1—dilated cardiomyopathy	1.59e-05	7.06e-05	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—EGFR—dilated cardiomyopathy	1.58e-05	7.03e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—EGFR—dilated cardiomyopathy	1.57e-05	7e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—ITGB1—dilated cardiomyopathy	1.57e-05	6.99e-05	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—EGFR—dilated cardiomyopathy	1.56e-05	6.96e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.56e-05	6.95e-05	CbGpPWpGaD
Vandetanib—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	1.54e-05	6.86e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—ADRB2—dilated cardiomyopathy	1.54e-05	6.84e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—RAC1—dilated cardiomyopathy	1.53e-05	6.82e-05	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—EGFR—dilated cardiomyopathy	1.53e-05	6.8e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—EGFR—dilated cardiomyopathy	1.52e-05	6.76e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.51e-05	6.72e-05	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TNF—dilated cardiomyopathy	1.5e-05	6.67e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.5e-05	6.65e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.5e-05	6.65e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—RAF1—dilated cardiomyopathy	1.49e-05	6.63e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	1.49e-05	6.63e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.48e-05	6.6e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—RAF1—dilated cardiomyopathy	1.47e-05	6.55e-05	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.47e-05	6.53e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.46e-05	6.51e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.46e-05	6.51e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—RAF1—dilated cardiomyopathy	1.46e-05	6.49e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.46e-05	6.47e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—RAF1—dilated cardiomyopathy	1.45e-05	6.46e-05	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TNF—dilated cardiomyopathy	1.45e-05	6.44e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.44e-05	6.41e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.44e-05	6.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—EGFR—dilated cardiomyopathy	1.44e-05	6.4e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—RAF1—dilated cardiomyopathy	1.44e-05	6.39e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—RAC1—dilated cardiomyopathy	1.44e-05	6.39e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.43e-05	6.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.43e-05	6.37e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—RAF1—dilated cardiomyopathy	1.42e-05	6.31e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.42e-05	6.31e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.42e-05	6.31e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—RAF1—dilated cardiomyopathy	1.41e-05	6.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—RAF1—dilated cardiomyopathy	1.41e-05	6.25e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.4e-05	6.24e-05	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—EGFR—dilated cardiomyopathy	1.4e-05	6.24e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.4e-05	6.24e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.4e-05	6.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.39e-05	6.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD36—dilated cardiomyopathy	1.39e-05	6.18e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—EGFR—dilated cardiomyopathy	1.39e-05	6.17e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.38e-05	6.14e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AGT—dilated cardiomyopathy	1.37e-05	6.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.36e-05	6.05e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD36—dilated cardiomyopathy	1.36e-05	6.05e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ITGB1—dilated cardiomyopathy	1.36e-05	6.04e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD36—dilated cardiomyopathy	1.36e-05	6.02e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.35e-05	6.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.35e-05	5.99e-05	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—EGFR—dilated cardiomyopathy	1.34e-05	5.97e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.34e-05	5.96e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD36—dilated cardiomyopathy	1.34e-05	5.96e-05	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—RAF1—dilated cardiomyopathy	1.33e-05	5.91e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.32e-05	5.86e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—RAC1—dilated cardiomyopathy	1.31e-05	5.85e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—RAC1—dilated cardiomyopathy	1.31e-05	5.83e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ITGB1—dilated cardiomyopathy	1.31e-05	5.82e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—RAF1—dilated cardiomyopathy	1.3e-05	5.78e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.3e-05	5.77e-05	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—EGFR—dilated cardiomyopathy	1.29e-05	5.74e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	1.28e-05	5.71e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—RAC1—dilated cardiomyopathy	1.28e-05	5.7e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RAC1—dilated cardiomyopathy	1.28e-05	5.7e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—RAC1—dilated cardiomyopathy	1.28e-05	5.68e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.27e-05	5.67e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—EGFR—dilated cardiomyopathy	1.27e-05	5.67e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—CD36—dilated cardiomyopathy	1.27e-05	5.66e-05	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.27e-05	5.63e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RAC1—dilated cardiomyopathy	1.27e-05	5.63e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—RAC1—dilated cardiomyopathy	1.26e-05	5.62e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AGT—dilated cardiomyopathy	1.26e-05	5.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.25e-05	5.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.25e-05	5.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—RAF1—dilated cardiomyopathy	1.24e-05	5.52e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	1.24e-05	5.5e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	1.23e-05	5.47e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AGT—dilated cardiomyopathy	1.22e-05	5.44e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AGT—dilated cardiomyopathy	1.21e-05	5.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—RAC1—dilated cardiomyopathy	1.21e-05	5.38e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.2e-05	5.34e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.2e-05	5.34e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—RAF1—dilated cardiomyopathy	1.2e-05	5.34e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—RAF1—dilated cardiomyopathy	1.2e-05	5.34e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—RAC1—dilated cardiomyopathy	1.2e-05	5.33e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—RAF1—dilated cardiomyopathy	1.2e-05	5.32e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PSEN2—dilated cardiomyopathy	1.2e-05	5.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—RAC1—dilated cardiomyopathy	1.19e-05	5.31e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.19e-05	5.3e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.19e-05	5.29e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—RAF1—dilated cardiomyopathy	1.18e-05	5.23e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.17e-05	5.22e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—RAC1—dilated cardiomyopathy	1.17e-05	5.18e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.16e-05	5.17e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.16e-05	5.15e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ITGB1—dilated cardiomyopathy	1.16e-05	5.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.16e-05	5.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD36—dilated cardiomyopathy	1.16e-05	5.15e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—EGFR—dilated cardiomyopathy	1.15e-05	5.13e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RAC1—dilated cardiomyopathy	1.15e-05	5.12e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.15e-05	5.11e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.15e-05	5.11e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AGT—dilated cardiomyopathy	1.14e-05	5.07e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—RAF1—dilated cardiomyopathy	1.14e-05	5.07e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—EGFR—dilated cardiomyopathy	1.13e-05	5.04e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—EGFR—dilated cardiomyopathy	1.13e-05	5.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.13e-05	5.01e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.12e-05	4.99e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—EGFR—dilated cardiomyopathy	1.12e-05	4.97e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—EGFR—dilated cardiomyopathy	1.12e-05	4.96e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCR3—dilated cardiomyopathy	1.12e-05	4.96e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD36—dilated cardiomyopathy	1.12e-05	4.96e-05	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.12e-05	4.96e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RAC1—dilated cardiomyopathy	1.11e-05	4.95e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGTR1—dilated cardiomyopathy	1.11e-05	4.93e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AGT—dilated cardiomyopathy	1.1e-05	4.89e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.09e-05	4.85e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—RAC1—dilated cardiomyopathy	1.09e-05	4.85e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRB1—dilated cardiomyopathy	1.08e-05	4.81e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—dilated cardiomyopathy	1.08e-05	4.8e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—dilated cardiomyopathy	1.07e-05	4.78e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—RAC1—dilated cardiomyopathy	1.07e-05	4.75e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.07e-05	4.75e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—dilated cardiomyopathy	1.06e-05	4.73e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AGT—dilated cardiomyopathy	1.06e-05	4.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGTR2—dilated cardiomyopathy	1.06e-05	4.73e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL2—dilated cardiomyopathy	1.06e-05	4.73e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—RAF1—dilated cardiomyopathy	1.06e-05	4.71e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.05e-05	4.68e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—ADRB2—dilated cardiomyopathy	1.05e-05	4.68e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—RAC1—dilated cardiomyopathy	1.05e-05	4.68e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.04e-05	4.64e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—EGFR—dilated cardiomyopathy	1.02e-05	4.55e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—RAF1—dilated cardiomyopathy	1.02e-05	4.52e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—EGFR—dilated cardiomyopathy	1.01e-05	4.5e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—RAC1—dilated cardiomyopathy	1.01e-05	4.48e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—EGFR—dilated cardiomyopathy	1e-05	4.45e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—EGFR—dilated cardiomyopathy	9.97e-06	4.43e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCR3—dilated cardiomyopathy	9.88e-06	4.39e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD36—dilated cardiomyopathy	9.88e-06	4.39e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—EGFR—dilated cardiomyopathy	9.86e-06	4.38e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—EGFR—dilated cardiomyopathy	9.82e-06	4.37e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—GPX1—dilated cardiomyopathy	9.75e-06	4.34e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—EGFR—dilated cardiomyopathy	9.72e-06	4.32e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—EGFR—dilated cardiomyopathy	9.72e-06	4.32e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—RAC1—dilated cardiomyopathy	9.71e-06	4.32e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—EGFR—dilated cardiomyopathy	9.69e-06	4.31e-05	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	9.62e-06	4.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.58e-06	4.26e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.57e-06	4.25e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—RAF1—dilated cardiomyopathy	9.53e-06	4.24e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—CD36—dilated cardiomyopathy	9.5e-06	4.22e-05	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—EGFR—dilated cardiomyopathy	9.47e-06	4.21e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.38e-06	4.17e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—RAC1—dilated cardiomyopathy	9.31e-06	4.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.23e-06	4.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—dilated cardiomyopathy	9.19e-06	4.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.18e-06	4.08e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRB2—dilated cardiomyopathy	9.09e-06	4.04e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.04e-06	4.02e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—EGFR—dilated cardiomyopathy	8.91e-06	3.96e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.76e-06	3.89e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—RAF1—dilated cardiomyopathy	8.72e-06	3.88e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—RAF1—dilated cardiomyopathy	8.69e-06	3.86e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—RAC1—dilated cardiomyopathy	8.59e-06	3.82e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	8.58e-06	3.82e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AGT—dilated cardiomyopathy	8.55e-06	3.8e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—RAF1—dilated cardiomyopathy	8.51e-06	3.78e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—RAF1—dilated cardiomyopathy	8.5e-06	3.78e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RAC1—dilated cardiomyopathy	8.47e-06	3.77e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—RAF1—dilated cardiomyopathy	8.47e-06	3.76e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—RAF1—dilated cardiomyopathy	8.4e-06	3.74e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—RAF1—dilated cardiomyopathy	8.37e-06	3.72e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CD36—dilated cardiomyopathy	8.36e-06	3.72e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RAC1—dilated cardiomyopathy	8.29e-06	3.69e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—EGFR—dilated cardiomyopathy	8.23e-06	3.66e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—EGFR—dilated cardiomyopathy	8.23e-06	3.66e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—EGFR—dilated cardiomyopathy	8.21e-06	3.65e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.17e-06	3.63e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RAC1—dilated cardiomyopathy	8.17e-06	3.63e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AGT—dilated cardiomyopathy	8.09e-06	3.6e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—RAF1—dilated cardiomyopathy	8.02e-06	3.57e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—RAF1—dilated cardiomyopathy	7.95e-06	3.53e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AGT—dilated cardiomyopathy	7.92e-06	3.52e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.92e-06	3.52e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—EGFR—dilated cardiomyopathy	7.88e-06	3.51e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—dilated cardiomyopathy	7.84e-06	3.48e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—EGFR—dilated cardiomyopathy	7.82e-06	3.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.81e-06	3.47e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AGT—dilated cardiomyopathy	7.8e-06	3.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.75e-06	3.45e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—RAF1—dilated cardiomyopathy	7.73e-06	3.44e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—RAF1—dilated cardiomyopathy	7.64e-06	3.4e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AGT—dilated cardiomyopathy	7.53e-06	3.35e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.52e-06	3.35e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—RAF1—dilated cardiomyopathy	7.38e-06	3.28e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—EGFR—dilated cardiomyopathy	7.27e-06	3.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—RAF1—dilated cardiomyopathy	7.24e-06	3.22e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—RAF1—dilated cardiomyopathy	7.09e-06	3.15e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RAC1—dilated cardiomyopathy	7.05e-06	3.14e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—EGFR—dilated cardiomyopathy	6.98e-06	3.1e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—RAF1—dilated cardiomyopathy	6.97e-06	3.1e-05	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.88e-06	3.06e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAC1—dilated cardiomyopathy	6.8e-06	3.02e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AGT—dilated cardiomyopathy	6.74e-06	3e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—RAF1—dilated cardiomyopathy	6.68e-06	2.97e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.66e-06	2.96e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—dilated cardiomyopathy	6.54e-06	2.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AGT—dilated cardiomyopathy	6.5e-06	2.89e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—RAF1—dilated cardiomyopathy	6.44e-06	2.86e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—RAF1—dilated cardiomyopathy	6.17e-06	2.74e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAC1—dilated cardiomyopathy	6.02e-06	2.68e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—dilated cardiomyopathy	5.98e-06	2.66e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—dilated cardiomyopathy	5.96e-06	2.65e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—dilated cardiomyopathy	5.83e-06	2.59e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—dilated cardiomyopathy	5.83e-06	2.59e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—dilated cardiomyopathy	5.81e-06	2.58e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—dilated cardiomyopathy	5.76e-06	2.56e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AGT—dilated cardiomyopathy	5.75e-06	2.56e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—dilated cardiomyopathy	5.74e-06	2.55e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—RAF1—dilated cardiomyopathy	5.7e-06	2.53e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—RAF1—dilated cardiomyopathy	5.62e-06	2.5e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—dilated cardiomyopathy	5.5e-06	2.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—RAF1—dilated cardiomyopathy	5.5e-06	2.45e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—RAF1—dilated cardiomyopathy	5.41e-06	2.41e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—dilated cardiomyopathy	5.3e-06	2.36e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—dilated cardiomyopathy	5.3e-06	2.35e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—dilated cardiomyopathy	5.24e-06	2.33e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—dilated cardiomyopathy	5.16e-06	2.29e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—dilated cardiomyopathy	5.06e-06	2.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—dilated cardiomyopathy	4.86e-06	2.16e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—dilated cardiomyopathy	4.78e-06	2.13e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RAF1—dilated cardiomyopathy	4.68e-06	2.08e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—dilated cardiomyopathy	4.64e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RAF1—dilated cardiomyopathy	4.51e-06	2e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—dilated cardiomyopathy	4.41e-06	1.96e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—dilated cardiomyopathy	4.23e-06	1.88e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RAF1—dilated cardiomyopathy	3.99e-06	1.77e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—dilated cardiomyopathy	3.91e-06	1.74e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—dilated cardiomyopathy	3.85e-06	1.71e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—dilated cardiomyopathy	3.77e-06	1.68e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—dilated cardiomyopathy	3.71e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—dilated cardiomyopathy	3.09e-06	1.37e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.86e-06	1.27e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.78e-06	1.24e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—dilated cardiomyopathy	2.74e-06	1.22e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.51e-06	1.11e-05	CbGpPWpGaD
